Metabolic Modulator · Cardioprotective · WADA S4

Meldonium
(Mildronate) Research

The Latvian cardiac drug that rewired Soviet athletics — and caught 99 athletes in a single month. A carnitine inhibitor that forces your cells to burn glucose instead of fat, producing more energy per oxygen molecule under hypoxic stress.

By MeetPeptide Research Team · Last updated March 2026
🚫
WADA Prohibited (S4 — Metabolic Modulators) since January 1, 2016. Not FDA-approved. Not available through licensed US pharmacies. Any competitive athlete subject to anti-doping rules must not use this compound. This page is for educational purposes only.
0
Published studies on Mildronate/Meldonium to date
0
Athletes tested positive within weeks of the 2016 WADA ban
1970s
Synthesized in Soviet Latvia — 50+ years of cardiovascular use

How Meldonium Works

Meldonium is a structural analogue of γ-butyrobetaine (GBB) — the natural precursor to L-carnitine. By mimicking GBB, it blocks the final enzyme in carnitine biosynthesis and forces a fundamental shift in cellular energy metabolism.

🧪
GBB Hydroxylase Inhibition
Meldonium inhibits γ-butyrobetaine dioxygenase (GBB) — the final enzyme converting GBB to L-carnitine. It acts as an alternative substrate (not just a blocker), consuming the enzyme's catalytic capacity via a radical mechanism.
🚫
OCTN2 Transporter Blockade
Simultaneously blocks SLC22A5 (OCTN2) — the primary carnitine transporter — preventing cellular uptake of dietary carnitine. The combined effect substantially depletes intracellular carnitine levels within days.
Fatty Acid → Glucose Shift
Without carnitine, long-chain fatty acids cannot enter the mitochondria for β-oxidation. Cells switch to glucose oxidation as their primary fuel — a less oxygen-demanding pathway that produces ~6.3 ATP per O₂ vs ~5.6 for fatty acids.
💨
Nitric Oxide Production
GBB accumulation (the substrate that builds up when GBB hydroxylase is blocked) stimulates endothelial NO synthase, increasing nitric oxide production. This causes vasodilation, improving blood flow to ischemic tissue.
🛡️
Acylcarnitine Toxicity Prevention
During ischemia, incomplete fatty acid oxidation produces toxic long-chain acylcarnitines that disrupt mitochondrial membranes and cause cell death. By blocking FA oxidation upstream, meldonium prevents this accumulation entirely.
🔋
Akt/GSK-3β Pathway Activation
Meldonium activates the Akt/GSK-3β pro-survival signaling pathway, providing anti-apoptotic effects in both cardiac and neural tissue. This contributes to its neuroprotective properties independent of the carnitine mechanism.
🥩
Fatty Acid Oxidation (Default)
~5.6
ATP produced per molecule of O₂ consumed. Dominant cardiac fuel (60–70% of cardiac ATP at rest). Requires carnitine as a transport shuttle. Produces toxic intermediates under ischemia.
🍬
Glucose Oxidation (With Meldonium)
~6.3
ATP produced per molecule of O₂ consumed — ~13% more efficient. No carnitine required. No acylcarnitine intermediates. The preferred fuel when oxygen is scarce — exactly when it matters most.

Why this matters under stress: During intense exercise, cardiac ischemia, or high-altitude conditions, oxygen delivery lags demand. Switching to glucose oxidation means the same amount of oxygen produces more ATP — potentially the difference between cardiac function and failure, or sustained performance and collapse.

What the Research Shows

Meldonium has an unusually robust clinical trial base for an Eastern European pharmaceutical, with approvals in over 10 countries and evidence across cardiovascular, cerebrovascular, and neurological indications.

Cardioprotection During Ischemia
Multiple RCTs and animal studies confirm reduced infarct size, preserved cardiac function during MI. Approved in 10+ countries for angina/CHF.
Strong
Exercise Tolerance in Heart Failure
MILSS I Trial: dose-dependent improvement in exercise tolerance in stable angina patients. Multiple CHF trials confirm improved functional capacity.
Strong
Cerebrovascular Protection / Stroke
RCT in acute ischemic stroke showed functional improvement. Animal MCAO model: reduced infarct volume, improved neurological scores via Akt pathway.
Moderate
Cognitive Function (Cerebrovascular Disease)
Improved mental quickness, short-term memory, P300 evoked potentials in chronic cerebrovascular disease patients (PMID 33244952). Benefits under hypoxic stress.
Moderate
Athletic Performance Enhancement
Plausible mechanism and anecdotal athlete use widespread. However, controlled RCTs in HEALTHY athletes are limited. Most data from cardiac/ischemic populations.
Weak/Theoretical
Neuroprotection — TBI, Huntington's, Parkinson's
Preclinical evidence in TBI (rat model), PGC-1α restoration in Huntington's model, motor improvement in Parkinson's models. Human data still emerging.
Preclinical
Right Ventricular Failure (2025 RCT)
Recent RCT (MDPI Biomedicines, 2025) — meldonium improved functional capacity in right ventricular failure, a condition with no currently approved pharmacotherapy.
Emerging

99 Athletes, One Month

When WADA added meldonium to its banned list on January 1, 2016, it triggered the largest single-drug doping scandal in sports history. The drug had been openly used by Eastern European athletes for decades — treating it as nothing more than a standard cardiovascular supplement.

1970s–2015
Routine Cardiovascular Use Across Eastern Europe
Meldonium prescribed routinely in Latvia, Russia, Ukraine, Belarus for angina, CHF, and stroke. Athletes given it by team physicians as a standard cardiovascular support. Grindeks (Latvia) earns €60–70M annually from exports. No oversight body had flagged it as a performance-enhancing drug.
January 1, 2016
WADA Ban Takes Effect — S4: Metabolic Modulators
WADA places meldonium on the prohibited list after monitoring data showed 2.2% prevalence (182 of 8,300 samples) among athletes in 2015. The ban covers in-competition and out-of-competition use with no TUE pathway recognized by most federations.
January 26, 2016
Maria Sharapova Tests Positive at Australian Open
The world's highest-paid female athlete tests positive for meldonium at the year's first Grand Slam. She announces the result herself at a press conference, stating she had taken Mildronate for 10 years under a physician's supervision for health reasons — a family history of diabetes, magnesium deficiency, and irregular EKG results. Her team claims they missed the January 1 ban addition.
March 2016
99+ Athletes Across 15 Sports Test Positive
Within weeks of Sharapova's announcement, WADA confirms 99 athletes had tested positive for meldonium. Athletes competed in 15 of 21 sports at the 2015 Baku European Games. 13 medalists or competition winners had been taking it. Of 662 positive samples reviewed, only 3.5% had properly declared use on doping control forms.
April 13, 2016
WADA Issues Threshold Guidance — Clearance Controversy
Amid pressure from athletes and national Olympic committees, WADA acknowledges meldonium "could take weeks or months to clear" from the body and issues a 100 ng/mL threshold for tests before March 1, 2016, leading to partial exonerations for athletes who could demonstrate prior use had been discontinued. The absence of a pre-established clearance timeline created a legal gray area.
October 2016
Court of Arbitration for Sport Reduces Sharapova Ban to 15 Months
CAS reduces the original 2-year ITF suspension to 15 months, finding she bore "less than significant fault" for the violation. Sharapova returns to tennis in April 2017. The case raises fundamental questions about athlete responsibility for monitoring prohibited list changes.
December 2024
Mykhailo Mudryk (Chelsea FC) Provisionally Suspended
Chelsea winger Mykhailo Mudryk receives a provisional suspension after reportedly testing positive for meldonium — demonstrating that Eastern European athlete use continues nearly a decade after the ban. Renewed attention to the drug's cultural embeddedness in Eastern European athletic medicine.

Dosing Protocols

Clinical dosing from Eastern European prescribing guidelines. These are not medical recommendations — meldonium is not approved for use in the US, EU, UK, Canada, or Australia.

❤️
Cardiovascular Indications
  • 500–1000mg/day orally (angina, CHF)
  • Typical: 500mg twice daily
  • Course length: 4–6 weeks, 2–3 courses/year
  • Acute ischemia: up to 2g IV in clinical settings
  • IV route: faster onset, 10% solution (5mL = 500mg)
  • Post-MI rehabilitation: standard oral protocol
🧠
Neurological / Cerebrovascular
  • Acute stroke: 500–1000mg IV daily × 10–14 days
  • Then transition to 500mg twice daily oral
  • Chronic cerebrovascular disease: 500mg 2×/day
  • Cognitive support: 4–6 week oral courses
  • Best studied in ischemic, not healthy populations
  • Neuroprotection mechanism: Akt/GSK-3β pathway
🏆
Athletic Use (Historical — Pre-Ban)
  • 500–1000mg/day orally, morning dose
  • Cycle: 4–6 weeks on, 2 weeks off minimum
  • Soviet military use at altitude: 500mg/day
  • Half-life ~3–6 hours — morning dosing standard
  • Fat-soluble? No — oral bioavailability ~78%
  • ⚠️ WADA BANNED — not for competitive athletes
⚗️
Pharmacokinetics
  • Oral bioavailability: ~78%
  • Tmax: ~1–2 hours post oral dose
  • Half-life: 3–6 hours (short)
  • Protein binding: low
  • Elimination: primarily renal
  • Detection window: weeks to months in urine (controversial)

Cycling rationale: Continuous use is not recommended because the body adapts by upregulating carnitine synthesis over time and efficacy diminishes. Periodic depletion/recovery cycles maintain the metabolic effect. Long-term continuous use in animal models has shown gut microbiome disruption.

Legal status: WADA Banned (S4) Rx — Eastern Europe Not FDA Approved Research Chemical (US)

Side Effects & Risk Assessment

Clinical safety data from Eastern European trials is generally favorable at therapeutic doses. Long-term safety in healthy users (non-cardiac populations) is not well-characterized.

GI Discomfort (Nausea, Bloating)
Mild GI effects reported in some patients; generally transient and dose-dependent
~8%
Headache / Dizziness
Likely related to vasodilatory effects (NO production). Typically mild and transient in clinical reports
~6%
Tachycardia (Elevated Heart Rate)
Rare; may occur due to compensatory mechanisms as cellular metabolism shifts. Caution in those with arrhythmia history
<3%
Long-Term Carnitine Depletion
Theoretical concern for prolonged use in healthy users. Clinical trials are 4–12 weeks; effects of multi-year depletion in non-cardiac patients are unknown
⚠️ Unknown
Overall Tolerability (Clinical Use)
Generally well-tolerated in cardiac patient populations at approved doses. Comparable to placebo in most reported adverse event profiles
Very Good

Drug Interactions: L-Carnitine supplementation directly competes with meldonium for OCTN2 transport, accelerating elimination and reducing meldonium's effect — relevant both for washout strategies and assessing whether carnitine co-supplementation is useful. Combining with nitrates or antihypertensives may potentiate hypotensive effects due to additive NO/vasodilatory action.


Contraindications: Severe renal impairment (primarily renally cleared). Pregnancy and lactation (insufficient data). Hypersensitivity to the compound.

Legal Status by Country

Meldonium's legal status reflects its unusual position — approved medicine in some countries, banned doping substance in sport worldwide, and unregulated gray-market compound elsewhere.

What We Know vs. What We Don't

Honest assessment of the evidence base — because distinguishing established science from speculation matters.

✅ What the Evidence Supports
  • Meldonium effectively inhibits carnitine synthesis — the biochemistry is well-established with crystallographic confirmation
  • Forces a shift to glucose metabolism — confirmed in vivo by hyperpolarized MRI studies (Savic et al., 2021)
  • Cardioprotective during ischemia — multiple RCTs in CHF and angina show improved exercise tolerance and cardiac function
  • Reduces acylcarnitine accumulation during ischemia — confirmed in animal and human studies
  • Approved medicine in 10+ countries for 40+ years with a generally clean safety profile at therapeutic doses
  • GBB accumulation increases NO production and has independent cardioprotective properties
  • Neuroprotective in acute stroke models and cerebrovascular disease patients
⚠️ What Remains Unknown
  • Performance enhancement in healthy athletes — plausible mechanism but no robust RCTs in healthy subjects (Schobersberger et al., 2017)
  • Long-term safety in non-cardiac populations — most trials 4–12 weeks; decades-long carnitine depletion effects unknown
  • Optimal cycling protocol — the 4–6 week cycles are empirical, not scientifically optimized
  • Interaction with modern cardiac medications — effects with statins, SGLT2 inhibitors, GLP-1 agonists unstudied
  • Urine detection window — individual variation in clearance time was the central WADA controversy
  • Benefits in healthy individuals vs. those with impaired cardiovascular/cerebrovascular function (selection bias in all trials)

Key Study Citations

Primary research behind the data on this page. Click PMID links to read full papers on PubMed.

Study 1 — Cardioprotection Mechanism
Mildronate, an inhibitor of carnitine biosynthesis, induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarction
Liepinsh E, et al. J Cardiovasc Pharmacol, 2006 Animal Study (Rat)
PMID: 17204911 DOI: 10.1097/01.fjc.0000250077
Study 2 — Comprehensive Mechanism Review
Pharmacological effects of meldonium: Biochemical mechanisms and biomarkers of cardiometabolic activity
Dambrova M, et al. Pharmacol Res, 2016 Review Article
DOI: 10.1016/j.phrs.2016.01.019
Study 3 — MILSS I Clinical Trial (Angina)
A dose-dependent improvement in exercise tolerance in patients with stable angina treated with mildronate: a clinical trial 'MILSS I'
Dzerve V, MILSS I Study Group Medicina (Kaunas), 2011 RCT — Human Clinical Trial
Medicina (Kaunas) 47(10):544-551
Study 4 — Neuroprotection (Stroke Model)
Meldonium, as a potential neuroprotective agent, promotes neuronal survival by protecting mitochondria in cerebral ischemia–reperfusion injury
Yang W, et al. J Transl Med, 2024 Animal Study (Rat MCAO)
PMC11325598 DOI: 10.1186/s12967-024-05222-7
Study 5 — Sports Medicine Review (WADA Ban)
Story behind meldonium — from pharmacology to performance enhancement: a narrative review
Schobersberger W, et al. Br J Sports Med, 2017 Narrative Review
DOI: 10.1136/bjsports-2016-096357
Study 6 — In Vivo Mechanism Confirmation (Hyperpolarized MRI)
Hyperpolarized MRI shows that meldonium leads to increased flux through pyruvate dehydrogenase in vivo, improving post-ischemic function in the diabetic heart
Savic D, et al. NMR Biomed, 2021 In Vivo Mechanistic Study
DOI: 10.1002/nbm.4471
Study 7 — L-Carnitine Drug Interaction
Carnitine and γ-Butyrobetaine Stimulate Elimination of Meldonium due to Competition for OCTN2-mediated Transport
Liepinsh E, et al. Basic Clin Pharmacol Toxicol, 2017 Drug Interaction Study
DOI: 10.1111/bcpt.12729
Study 8 — Cognitive Effects in Cerebrovascular Disease
Chronic cerebrovascular diseases and neuroprotection: clinical efficacy of meldonium (Mildronat) — improved mental quickness, memory, P300 evoked potentials
Zh Nevrol Psikhiatr Im S S Korsakova, 2020 Human Clinical Data

🛒 Recommended Supplements

Relevant products for meldonium protocols and mitochondrial support. Affiliate links help support MeetPeptide at no extra cost to you.

🧬 L-Carnitine Replenishes carnitine depleted by meldonium. Controversial combo — see drug interaction notes above. ⚡ CoQ10 (Ubiquinol) Mitochondrial electron transport chain cofactor. Supports cellular energy production when fatty acid oxidation is reduced. 🧠 Acetyl-L-Carnitine (ALCAR) Brain-penetrant carnitine form. Cognitive support and neuroprotection. The carnitine form most relevant to brain function. 🌿 Magnesium Glycinate Sharapova's physician cited magnesium deficiency as one reason for prescribing Mildronate. Cofactor for hundreds of metabolic reactions. 🔋 Alpha Lipoic Acid Mitochondrial antioxidant. Reduces ROS from metabolic shifts. Supports both glucose and FA pathways. Often stacked with carnitine and CoQ10.

Amazon affiliate links — we earn a small commission at no extra cost to you. Product recommendations are based on relevance to this topic, not paid placement.

Explore Related Research

Other compounds in the nootropic, metabolic, and Soviet-era performance research space.

Educational Disclaimer: This page is for educational and informational purposes only. Meldonium (Mildronate) is not approved by the FDA or EMA and is not available through licensed pharmacies in the United States, European Union, United Kingdom, Canada, or Australia. It is a WADA-prohibited substance (S4: Metabolic Modulators) — any competitive athlete subject to anti-doping rules must not use this compound. Nothing on this page constitutes medical advice, and MeetPeptide does not encourage the use of prohibited or unapproved substances. Always consult a licensed physician before making any changes to your health protocols. Information presented reflects publicly available research literature as of March 2026.